{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:35:58Z","timestamp":1715974558684},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,4,8]],"date-time":"2011-04-08T00:00:00Z","timestamp":1302220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s12149-011-0488-9","type":"journal-article","created":{"date-parts":[[2011,4,7]],"date-time":"2011-04-07T23:24:54Z","timestamp":1302218694000},"page":"469-477","source":"Crossref","is-referenced-by-count":9,"title":["Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET\/CT? Results from small population with previous breast cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Laura","family":"Evangelista","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zora","family":"Baretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Vinante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Cervino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Gregianin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ghiotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Bozza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Saladini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,8]]},"reference":[{"key":"488_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/ctrv.1999.0151","volume":"26","author":"KL Cheung","year":"2000","unstructured":"Cheung KL, Graves CR, Robertson JF. Tumour marker measurement in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000;26:91\u20132.","journal-title":"Cancer Treat Rev"},{"key":"488_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00690183","volume":"36","author":"R Molina","year":"1995","unstructured":"Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu\u00f1oz M, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat. 1995;36:41\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"488_CR3","first-page":"4485","volume":"19","author":"F Lumachi","year":"1999","unstructured":"Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D\u2019Amico DF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15.3. Anticancer Res. 1999;19:4485\u201390.","journal-title":"Anticancer Res"},{"issue":"1","key":"488_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0305-7372(03)00141-5","volume":"30","author":"RF Collins","year":"2004","unstructured":"Collins RF, Bekker HL, Dodwell DJ. Follow-up care of patients treated for breast cancer: a structured review. Cancer Treat Rev. 2004;30(1):19\u201335.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"488_CR5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","volume":"52","author":"MJ Duffy","year":"2006","unstructured":"Duffy MJ. Serum tumour markers in breast cancer: are they of clinical value? Clin Chem. 2006;52(3):345\u201351.","journal-title":"Clin Chem"},{"key":"488_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01806524","volume":"13","author":"R Colomer","year":"1989","unstructured":"Colomer R, Ruibal A, Genoll\u00e1 J, Rubio D, Del Campo JM, Bodi R, et al. Circulating CA 15.3 levels in the post surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat. 1989;13:123\u201333.","journal-title":"Breast Cancer Res Treat"},{"key":"488_CR7","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/0959-8049(93)90309-4","volume":"29","author":"S Kleist Von","year":"1993","unstructured":"Von Kleist S, Bombardieri E, Buraggi G, Gion M, Hertel A, Hor G, et al. Immunodiagnosis of tumours. Eur J Cancer A. 1993;29:1622\u201330.","journal-title":"Eur J Cancer A"},{"key":"488_CR8","first-page":"113","volume":"46","author":"M Su\u00e1rez","year":"2002","unstructured":"Su\u00e1rez M, P\u00e9rez-Castej\u00f3n MJ, Jim\u00e9nez A, Domper M, Ruiz G, Montz R, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med. 2002;46:113\u201321.","journal-title":"Q J Nucl Med"},{"key":"488_CR9","doi-asserted-by":"crossref","unstructured":"Evangelista L, Baretta Z, Vinante L, Cervino AR, Gregianin M, Ghiotto C, et al. Tumour markers and FDG PET\/CT for prediction of disease relapse in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:293\u2013301.","DOI":"10.1007\/s00259-010-1626-7"},{"key":"488_CR10","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:1\u201318.","DOI":"10.1200\/JCO.2007.14.2364"},{"key":"488_CR11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2967\/jnumed.109.074294","volume":"51","author":"Z Rabkin","year":"2010","unstructured":"Rabkin Z, Israel O, Keidar Z. Do hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG\/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysis. J Nucl Med. 2010;51:1015\u201320.","journal-title":"J Nucl Med"},{"key":"488_CR12","unstructured":"Diamonds EP, Fritsche HA, Lilja H, Chau DW, Shwartz MK. Tumour markers. Physiology, pathobiology, technology and clinical applications. American Association of Clinical Chemistry; 2002."},{"key":"488_CR13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ejca.2003.10.015","volume":"40","author":"G Soletormos","year":"2004","unstructured":"Soletormos G, Nielsen D, Schioler V, Mouridsen H, Dombernowsky P. Monitoring different stages of breast cancer using tumour markers CA 15.3, CEA and TPA. Eur J Cancer. 2004;40:481\u20136.","journal-title":"Eur J Cancer"},{"key":"488_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1054\/brst.1999.0154","volume":"9","author":"M Given","year":"2000","unstructured":"Given M, Scott M, Mc Grath JP, Given HF. The predictive value of tumour markers Ca 15.3, TPS and CEA in breast cancer recurrence. Breast. 2000;9:277\u201380.","journal-title":"Breast"},{"key":"488_CR15","doi-asserted-by":"crossref","unstructured":"Anonymous. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol. 1996;14:2843\u201377.","DOI":"10.1200\/JCO.1996.14.10.2843"},{"issue":"2","key":"488_CR16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/13547500902770090","volume":"14","author":"L Mariani","year":"2009","unstructured":"Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrence. Biomarkers. 2009;14(2):130\u20136.","journal-title":"Biomarkers"},{"key":"488_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1095-0397(00)00050-9","volume":"3","author":"KF Hubner","year":"2000","unstructured":"Hubner KF, Smith GT, Thie JA, Bell JL, Nelson HS, Hanna WT. The potential of 18F-FDG PET in breast cancer. Detection of primary lesions, axillary lymph node metastases, or distant metastases. Clin Positron Imaging. 2000;3:197\u2013205.","journal-title":"Clin Positron Imaging"},{"issue":"9\u201310","key":"488_CR18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/sj.bjc.6690230","volume":"79","author":"A Nicolini","year":"1999","unstructured":"Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999;79(9\u201310):1443\u20137.","journal-title":"Br J Cancer"},{"key":"488_CR19","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2001.19.15.3516","volume":"19","author":"WB Eubank","year":"2001","unstructured":"Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, et al. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 2001;19:3516\u201323.","journal-title":"J Clin Oncol"},{"key":"488_CR20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-004-3291-7","volume":"90","author":"CR Isasi","year":"2005","unstructured":"Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90:105\u201312.","journal-title":"Breast Cancer Res Treat"},{"key":"488_CR21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s002680020095","volume":"25","author":"TS Kim","year":"2001","unstructured":"Kim TS, Moon WK, Lee DS, Chung JK, Lee MC, Youn YK, et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg. 2001;25:829\u201334.","journal-title":"World J Surg"},{"key":"488_CR22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11307-005-0013-4","volume":"7","author":"BJ Fueger","year":"2005","unstructured":"Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, et al. Performance of 2-deoxy-2-F-18-fluoro-d-glucose positron emission tomography and integrated PET\/CT in restaged breast cancer patients. Mol Imaging Biol. 2005;7:369\u201376.","journal-title":"Mol Imaging Biol"},{"key":"488_CR23","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.1998.16.10.3375","volume":"16","author":"GJ Cook","year":"1998","unstructured":"Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman J. Detection of bone metastases in breast cancer by FDG PET. Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375\u20139.","journal-title":"J Clin Oncol"},{"key":"488_CR24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF02303744","volume":"4","author":"OA Ogunbiyi","year":"1997","unstructured":"Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum EH, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613\u201320.","journal-title":"Ann Surg Oncol"},{"key":"488_CR25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","volume":"26","author":"R Molina","year":"2005","unstructured":"Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer\u2014European Group on tumor markers recommendations. Tumor Biol. 2005;26:281\u201393.","journal-title":"Tumor Biol"},{"key":"488_CR26","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/6.suppl_2.S31","volume":"6","author":"M Gion","year":"1995","unstructured":"Gion M, Barioli P, Mione R, Cappelli G, Vignati G, Fortunato A, et al. Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Ann Oncol. 1995;6:S31\u20135.","journal-title":"Ann Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-011-0488-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-011-0488-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-011-0488-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T08:35:48Z","timestamp":1637483748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-011-0488-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,8]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s12149-011-0488-9","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,8]]}}}